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Objective: To identify potential risk factors associated with Candida infections and
compare these risk factors between patients who both died and survived.
Study design: A group of patients with positive Candida spp. blood cultures admitted
to a neonatal intensive care unit (NICU) in Costa Rica between January 1994 and
December 1998. Cases were identified through a computerized search of the micro-
biology laboratory’s database on blood cultures.
Results: One hundred and ten newborns were identified. Sixty-six patients (60%) were
male; 46 (62%) were preterm infants. Thirty-seven (34%) patients died. Twenty (54%)
of them died within three days of the candidemia diagnosis and 17 had disseminated
Candida infection on autopsy. Candida albicans and Candida tropicalis were isolated
in 90% and 10% of blood cultures, respectively. Mean  SD (range) number of days from
admission to NICU to the initial positive blood culture were 13.5  8.5 (1—30) days.
Most patients had at least two positive blood cultures (range 1—8). Median (range)
days for the sterilization of blood culture were four (1—25) days. Significant differ-
ences in survival were identified in patients with axillary-inguinal lesions, apnea and
seizures.t at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco,
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Since the early 1980s the survival rate of preterm
infants has dramatically improved. However, this
has resulted in the emergence of secondary infec-
tions such as those caused by Candida spp. This
organism plays an important pathogenic role in
neonatal intensive care units (NICU), and it repre-
sents the third most common cause of late-onset
sepsis in NICU patients.1 More importantly, approxi-
mately 1—3% of these newborns have birth weights
<1500 g.2,3 Candida species may be acquired verti-
cally from the mother or after colonization in the
NICUs.4,5
Although fungemia is the most common presenta-
tion, Candida spp. can disseminate and produce
other types of infections, includingmeningitis; renal,
splenic or hepatic abscesses; endophthalmitis, osteo-
myelitis or invasive dermatitis. The grossmortality of
fungal infections in NICUs ranges from 25—50%6,7
Furthermore, a delay in the recognition of Candida
infections and the initiationof appropriateantifungal
therapy often leads to significant morbidity andmor-
tality rates among high-risk infants.8
The objectives of this study were to identify
potential risk factors associated with Candida infec-
tions in the NICU at the Costa Rican National Chil-
dren’s Hospital and to compare these risk factors
between patients who died and survived. These
results may be used to elaborate guidelines to pre-
vent these serious infections and improve their
diagnosis and management.Materials and methods
This was a retrospective study of patients who were
admitted to the NICU and had a positive Candida
blood culture. Cases were identified by reviewing
the hospital’s records of laboratory cultures. NICU
patients who had had candidemia between January
1994 and December 1998 were included in this
study.
Definition of terms7—9
Candidemia: the growth of Candida species from
peripheral or central venous blood samples. It was
considered contributory to mortality if death
occurred within three days of a positive blood cul-ture or if there was evidence of disseminated can-
didiasis in the autopsy.
Congenital candidiasis: neonatal candidiasis
acquired during passage through an infected birth
canal or in utero. Lesions appear after the first week
of life, and commonly include thrush, perianal and
diaper dermatitis.
Axillary-inguinal lesions: erythematous macules,
papules and pustules overlying areas of confluent
macular erythema distributed on axillary and/or
inguinal areas.
Apnea: an abnormal respiratory pause of at least
20 seconds or associated with cyanosis, marked
pallor, hypotonia or bradycardia.
Mucositis: inflammation of the mucous mem-
branes lining the digestive tract from the mouth
to the anus.
Abdominal distention: an increase in abdominal
circumference, usually due to gas in the intestinal
tract.
Fever: axillary temperature above 37.5 8C.
Bleeding: extravasation of blood or plasma from
mucous membranes, organs or puncture sites.
Hypothermia: axillary temperature 36 8C.
Reference ranges used for blood values were:
Thrombocytopenia: Less than 150  109/L
Anemia: Hemoglobin less than 10 g/dL
Leukocytosis: leukocytes more than 15  109/L
Leukopenia: leukocytes less than 5  109/L
Hyperglycemia: glucose more than 116 mg/dL
Hypoglycemia: glucose less than 50 mg/dL
Medical records were reviewed to collect the f-
ollowing information: demographic characteristics,
use of parenteral nutrition and antibiotics, number
and duration of invasive procedures (such as surgery,
endotracheal intubation and intravascular devices)
and length of hospitalization.
Additional data included: age, onset of fungal
infection, clinical signs and symptoms, laboratory
tests, identification of the causative organism, anti-
fungal therapy and complications.
Data were collected in standardized forms,
entered and analysed with Epistat True 4.0 soft-
ware. Categorical variables were compared using
contingency 2  2 tables, by Chi-square and log-
likelihood ratio; 95% confidence intervals were cal-
culated. A p value of 0.05 was considered statis-
tically significant.
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Table 1 Clinical manifestations in newborns with candidemia.
Clinical findings Survived N (%)
N = 73 (66)*
Died N (%)
N = 37 (34)
Total N (%)
N = 110 (100)
p value
Axillary-inguinal lesions 39 (53) 27 (73) 66 (60) 0.007
Mucositis 40 (55) 23 (62) 63 (57) NS
Abdominal distention 43 (59) 20 (54) 63 (57) NS
Cyanosis 32 (44) 23 (62) 55 (50) NS
Fever 27 (37) 23 (62) 50 (45) 0.02
Apnea 25 (34) 23 (62) 48 (44) 0.009
Bleeding 10 (14) 10 (27) 20 (18) NS
Hypothermia 7 (10) 10 (27) 17 (15) 0.03
Rash 15 (21) 13 (35) 28 (25) NS
Seizures 7 (10) 12 (32) 19 (17) 0.006
NS: not significant.
* Number of patients (percentages in parenthesis).Results
One hundred and ten newborn patients who had a
positive Candida blood culture were identified and
analysed. Sixty percent (66/110) were male and 62%
were premature infants. Thirty-four percent (37/
110) died, 20 of whom (54%) died within three days
of the diagnosis of fungemia.
Forty-six percent (17/37) of patients who died
had evidence of disseminated fungal infection at
autopsy, of whom seven (41%) died within three days
of the Candida diagnosis. More importantly, Candida
was a contributory factor to mortality in 29/37 (78%)
patients. Of all the patients who died, seven had
congenital candidiasis. Patients with congenital
infection had an erythematous maculopapular or
vesicular rash with or without pneumonia, and diag-
nosis was made as early as three days after birth
(range 1—5 days).
Clinical manifestations associated with candide-
mia are presented in Table 1. Significant differences
between those patients who survived and died were
identified: axillary-inguinal lesions, apnea and sei-
zures. The most common manifestations were: skin
lesions, 66/110 (60%); mucositis, 63 (57%); abdom-
inal distention, 63 (57%); cyanosis, 55 (50%) and
fever, 50 (45%). Other manifestations included
apnea, hypothermia, and skin rash.Table 2 Laboratory findings in newborns with candidemia.
Laboratory findings Survived N (%) N = 73 (66)*
Thrombocytopenia 64 (88)
Anemia 20 (27)
Leukocytosis 16 (22)
Hypoglycemia 15 (21)
Leukopenia 7 (10)
Hyperglycemia 2 (3)
There were no statistical differences.
* Number of patients (percentages in parenthesis).Laboratory findings are shown in Table 2. There
were no significant differences in any of these
laboratory tests among infants who survived or died.
Although only five patients had a cerebrospinal fluid
(CSF) culture positive for C. albicans, many patients
had one or more abnormal findings in the CSF as
shown in Table 3.
Candida albicans accounted for 90% of the posi-
tive blood cultures and C. tropicalis accounted for
the remaining 10%. Antifungal drug susceptibility
testing was not performed. Forty-six percent (17/
37) of newborns who died had a positive blood
culture post-mortem.
Mean  SD days between admission to the NICU
and initial positive culture were 13.5 days (4)
(range 1—20 days). Seventy-five percent (82/110)
of patients had at least two positive cultures during
the course of infection. The median length for the
sterilization of blood cultures was four days (range
1—25 days).
Table 4 shows the risk factors identified in these
patients: previous use of antibiotics in 95%, endo-
tracheal intubation for a mean of nine days in 64%,
use of central devices including umbilical lines for a
mean of eight days in 89%, and parenteral nutrition
for a mean of 12 days in 84% of patients. Other risk
factors identified were abdominal and thoracic sur-
gery. Regarding risk factors, there were no signifi-Died N (%) N = 37 (34) Total N (%) N = 110 (100)
17 (46) 81 (74)
15 (41) 35 (32)
15 (41) 31 (28)
15 (41) 30 (27)
10 (27) 17 (15)
2 (5) 4 (4)
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Table 3 Laboratory findings in CSF samples from newborns with candidemia.
Laboratory findings Survived N = 73 (66%)** Died N = 37 (34%)
Leukocytes (cells/mm3)* 10  15 (0—25) 8  6 (0—15)
Protein (mg/dL)* 77  68 (45—155) 67  70 (50—145)
Decreased glucose** 20 (54) 43 (59)
Positive culture 0 5
p > 0.5.
* Mean  SD (range).
** Number of patients (%).
Table 4 Risk factor identified in newborns with candidemia.
Factor Number of patients N (%) N = 110 Mean  SD days Range days
Previous use of antibiotics 105 (95) 14  6 3—65
Central catheters 98 (89) 8  5 1—35
Parenteral nutrition 92 (84) 12  8 2—40
Tracheal intubation 70 (64) 9  6.8 5—35
Other factors identified: abdominal surgery: 40 (35%); thoracic surgery: 39 (35%).cant differences between those who survived and
those who died.
All patients received amphotericin B 0.5 mg/kg
during the first day and then 1 mg/kg for a
mean  SD of 17 days (7), (range 10—23 days).
Fluconazole was used in combination with ampho-
tericin B in 15/110 (14%) cases for a median of 12
days, (range 8—27 days); and 5-flucytosine plus
amphotericin B in nine cases (8%), for a median of
three days, (range 2—6 days). No adverse events
were reported with any of these drugs. Additionally,
no differences regarding outcome were identified
between antifungal therapies.Discussion
Newborns admitted to intensive care units are at
greater risk of contracting nosocomial infections.
These risks are associated with their susceptibility
to infections as a result of both prematurity and
invasive medical equipment needed for survival.
Rates of Candida bloodstream infections have
increased dramatically during the past decade, in
part related to the improvement in survival rates of
infants with very low birth weights.8
Other risk factors associated with candidiasis
include immunocompromized hosts, early fungal
gastrointestinal tract colonization, predisposition
to invasive fungal dermatitis, and use of parenteral
antibiotics and corticosteroids.9
In this study the following were identified as risk
factors: use of broad-spectrum antibiotics, endo-
tracheal intubation, use of central lines, parenteral
nutrition and abdominal or thoracic surgery. Nodifferences were identified between those patients
who survived and those who died.
Previously it has been established that the type
and number of antibiotics such as third generation
cephalosporins,10 vancomycin11 or carbapenems12
can predispose to Candida infections, especially in
immunocompromized hosts. The data here con-
firmed these reports. Use of multiple invasive
devices, such as catheters and endotracheal tubes
may be responsible for the nosocomial spread of
pathogens through the hands of healthcare workers
(HCW). Because this was a retrospective study,
samples from potentially colonized HCW in the unit
were not obtained. More importantly, during the
period of this study, parenteral nutrition including
lipids was given without the use of appropriate
filters, contributing to a potentially important
extrinsic mechanism of infection/contamination in
this population. The hands of HCW and environmen-
tal surfaces are newly-appreciated potential reser-
voirs for nosocomial strains of Candida. More
importantly, preventive measures such as the use
of filters for parenteral nutrition, and a restrictive
policy of antibiotic use to decrease Candida coloni-
zation/infection rates, should be implemented to
reduce the morbidity and mortality associated with
these infections.
Even though candidemia has been associated
with prolonged hospitalization, most fatal cases
occurred in neonates younger than three weeks of
age.8,13,14 Given that infants of this age have
decreased immunity, their host response to Candida
may contribute to mortality.15,16
Candida albicans is the most common cause of
candidemia. It may be vertically transmitted from
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comial infection from several Candida species, such
as C. albicans, has been well studied. In this report
10% of patients had C. tropicalis candidemia, which
may be acquired by horizontal transmission. Its
ability to produce clusters has been one of its major
pathogenic components. However, C. tropicalis has
not been thoroughly studied and could potentially
play an important role in nosocomial infections.20,21
Few patients had candidemia by species other than
C. albicans; however, mortality was higher in new-
borns infected with C. albicans.
Even though Candida vaginitis occurs in 20—30%
of pregnancies, it does not usually produce obstetric
complications.22 This was an unexpected finding
since mortality rates in congenital candidiasis have
been lower in previous reports. In premature neo-
nates weighing <1000 g, the risk of systemic fungal
infection reported is 67% andmortality is 40%. This is
in contrast to premature newborns weighing
>1000 g where the risk of systemic infection and
death is 10% and 8%, respectively.22,23 Moreover,
invasive fungal dermatitis is a disease of the smal-
lest and most immature neonates. This is usually
associated with vaginal birth, steroid administra-
tion, and hyperglycemia.23 As with previous studies,
it is believed that the skin serves as a portal of entry
for colonizing fungal species and may lead to dis-
seminated infection. Life-threatening disseminated
candidiasis can occur, with death in the immediate
neonatal period, as seen in this and previous
reports.4 The mortality rate associated with these
infections is 20—50% and occurs among all ages. In
this report, the mortality rate was 34%.
Monotherapy with amphotericin B appeared to be
effective in most cases.24,25 Occasionally a second
antifungal agent may be needed for persistent can-
didemia, as occurred in 24 patients from this series.
Most of the clinical characteristics of candidemia
in this study were similar to previous publications.
However, it was identified here that the finding of
axillary and inguinal lesions, apnea and seizures
were more common in those patients who died.
Due to this new finding and the limitation of this
type of study, future prospective case-control stu-
dies should be carried out to confirm this finding.
Abnormal CSF findings also deserve further consid-
eration. Diagnosis of fungal meningitis is important
since it mandates adjustments in antifungal ther-
apy. Many CSF samples had one or more cytologic or
biochemical abnormalities, which might suggest
that more patients had fungal intracranial involve-
ment, despite negative CSF culture. Negative cul-
tures in the presence of CSF abnormalities could
reflect a partially treated fungal meningitis or may
represent the inherent difficulties for this microor-ganism to grow from a small CSF sample, lower
inoculum size or improper use of special isolation
techniques.26,27
In conclusion, invasive candidiasis is frequent in
NICUs, and it is associatedwith highmortality rates in
premature newborns in Costa Rica. Ongoing epide-
miological surveys have increased the understanding
of reservoirs and modes of transmission of Candida
spp. Continued surveillance is necessary to estimate
the real incidence and impact of this infection.
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